Analyst initiations: SOLF, BMRN and DNA

MOST NOTEWORTHY: Solarfun Power, BioMarin Pharmaceutical and Genentech were today's noteworthy initiations:

Jefferies initiated Solarfun Power (NASDAQ:SOLF) with a Buy rating and $18 target. The firm believes the one-third stake purchased by Good Energies and new management hires could generate operational momentum and that declining silicon costs may help margins.
BioMarin Pharmaceutical (NASDAQ:BMRN) was started at Oppenheimer with a Perform rating. The firm recommends waiting for Street estimates on Kuvan sales to moderate and for positive pipeline signals before adding to positions.
Genentech (NYSE:DNA) was initiated at Citigroup with a Buy rating and $91 target. The firm believes several studies could lead to robust growth and points out the company's Q2 results showed Avastin reaccelerating due to growth in breast cancer.

OTHER INITIATIONS:

Goldman reinstated Staples (NASDAQ:SPLS) with a Neutral rating.
Zebra Tech (NASDAQ:ZBRA) was initiated with a Hold rating at KeyBanc.
Rodman & Renshaw assumed coverage of Corcept Therapeutics (NASDAQ:CORT) with an Outperform rating and $8 target.
AuthenTec (NASDAQ:AUTH) was initiated at JP Morgan with an Overweight rating and at Canaccord Adams with a Hold rating and $10 target.

Tags: analyst initiations, AnalystInitiations, AUTH, BRMN, CORT, DNA, inthenews, SOLF, SPLS, ZBRA

#	Blogger	Posts	Cmts
1	Joseph Lazzaro	122	0
2	Connie Madon	53	0
3	Steven Mallas	51	0
4	Mark Fightmaster	38	0
5	Tom Taulli	37	0
6	Trey Thoelcke	35	0
7	Brian White	31	1
8	Tom Johansmeyer	31	0
9	Steven Halpern	27	0
10	Melly Alazraki	25	0
11	Paul Foster	25	0
12	Eric Buscemi	21	0
13	Jon Ogg	21	0
14	Zac Bissonnette	21	0
15	Brent Archer	18	0
16	Elizabeth Harrow	17	0
17	Michael Fowlkes	14	0
18	Sheldon Liber	11	0
19	Louis Navellier	11	0
20	Beth Gaston Moon	8	0